<p>Ardelyx, Inc.（纳斯达克代码：ARDX - 获取免费报告）首席执行官 Michael Raab 于 3 月 16 日（星期一）出售了 41,666 股公司股票。股票的平均售价为 5.84 美元，总价值为 243,329.44 美元。交易完成后，首席执行官直接持有公司 1,816,448 股，价值为 10,608,056.32 美元。这代表其持股比例减少了 2.24%。此次出售在提交给证券交易委员会的文件中披露，您可以通过此链接访问该文件。</p>
<ul>
<li>华尔街喜爱的 3 只市值低于 20 美元的中型股</li>
</ul>
<p>Michael Raab 最近还进行了以下交易：</p>
<ul>
<li>在 2 月 20 日（星期五），Michael Raab 出售了 45,982 股 Ardelyx 股票。股票的平均售价为 5.85 美元，总价值为 268,994.70 美元。</li>
</ul>
<h2>Ardelyx 股价下跌 4.8%</h2>
<p>在周三的午盘交易中，ARDX 股票下跌 0.28 美元，达到 5.55 美元。该公司的股票交易量为 2,907,115 股，而其平均交易量为 4,895,942 股。Ardelyx, Inc.的 12 个月最低价为 3.21 美元，最高价为 8.40 美元。该公司的流动比率为 4.31，速动比率为 4.11，债务与股本比率为 1.21。该公司的 50 日移动平均价格为 6.88 美元，200 日移动平均价格为 6.16 美元。该公司的市值为 13.6 亿美元，市盈率为-22.20，贝塔值为 0.61。</p>
<ul>
<li>Ardelyx 在 2022 年初下滑后是否值得购买</li>
</ul>
<p>Ardelyx（纳斯达克代码：ARDX - 获取免费报告）最近在 2 月 19 日（星期四）发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为-0.01 美元，低于分析师一致预期的 0.02 美元，差距为 0.03 美元。该公司的季度收入为 1.2522 亿美元，而一致预期为 1.1804 亿美元。Ardelyx 的股本回报率为-40.63%，净利润率为-15.12%。Ardelyx 的季度收入同比增长 7.8%。在去年同期，该公司每股收益为 0.02 美元。根据分析师的预测，Ardelyx, Inc.在当前年度的每股收益将为-0.18 美元。</p>
<h2>分析师评级升级与降级</h2>
<p>几位研究分析师最近对该股票发布了报告。Raymond James Financial 在 1 月 8 日（星期四）的研究报告中重申了对 Ardelyx 的 “强力买入” 评级，并设定了 19.00 美元的目标价。Leerink Partners 在 3 月 12 日（星期四）的研究报告中重申了对 Ardelyx 的 “跑赢大盘” 评级。Weiss Ratings 在 1 月 21 日（星期三）的报告中重申了对 Ardelyx 的 “卖出（d-）” 评级。Williams Trading 在 3 月 12 日（星期四）的研究报告中设定了 17.00 美元的目标价。最后，花旗集团在 1 月 9 日（星期五）的研究报告中将 Ardelyx 的目标价从 11.00 美元上调至 14.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股票给予了强力买入评级，八位分析师给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 15.70 美元。</p>
<p><strong>获取我们对 ARDX 的最新股票分析</strong></p>
<h2>机构资金流入与流出</h2>
<p>一些对冲基金最近对 ARDX 的持仓进行了调整。DCF Advisers LLC 在第二季度收购了 Ardelyx 的新股份，价值约 39,000 美元。First Horizon Corp 在第四季度将其在 Ardelyx 的持股增加了 120.4%。First Horizon Corp 目前持有 7,906 股生物制药公司的股票，价值 46,000 美元，此前在上个季度购买了 4,319 股。SBI Securities Co. Ltd.在第三季度将其在 Ardelyx 的持股增加了 147.0%。SBI Securities Co. Ltd.目前持有 10,253 股生物制药公司的股票，价值 56,000 美元，此前在上个季度购买了 6,102 股。瑞士人寿资产管理有限公司在第三季度收购了 Ardelyx 的新股份，价值约 57,000 美元。最后，住友三井信托集团在第四季度收购了 Ardelyx 的新股份，价值约 60,000 美元。目前 58.92% 的股票由机构投资者和对冲基金持有。</p>
<h2>Ardelyx 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ardelyx, Inc.（纳斯达克：ARDX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对心肾和胃肠疾病的小分子靶向药物。该公司的主要市场产品 tenapanor（在美国以品牌名 XPHOZAH 销售）已获批准用于治疗接受透析的慢性肾病患者的高磷血症。Ardelyx 的专有方法针对胃肠道中的上皮转运蛋白，提供局部作用并限制全身暴露。</p>
<p>除了 tenapanor，Ardelyx 的开发管道还包括旨在解决肾病及相关代谢紊乱的其他并发症的治疗方案。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Ardelyx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ardelyx 吗？</h2>
<p>在你考虑 Ardelyx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ardelyx 并不在名单上。</p>
<p>虽然 Ardelyx 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

ARDX

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

<p>Ardelyx, Inc. 首席执行官 Michael Raab 出售了 41,666 股股票，平均价格为 5.84 美元，总计 243,329.44 美元，导致其持股比例减少 2.24%。出售后，他持有 1,816,448 股，价值约 1060 万美元。该股票最近下跌 4.8%，报 5.55 美元，市值为 13.6 亿美元。分析师对该股票的评级不一，普遍目标价为 15.70 美元。机构投资者最近也对 Ardelyx 股票的持仓进行了调整</p>

<p>Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the transaction, the chief executive officer directly owned 1,816,448 shares in the company, valued at $10,608,056.32. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（纳斯达克代码：ARDX - 获取免费报告）首席执行官 Michael Raab 于 3 月 16 日（星期一）出售了 41,666 股公司股票。股票的平均售价为 5.84 美元，总价值为 243,329.44 美元。交易完成后，首席执行官直接持有公司 1,816,448 股，价值为 10,608,056.32 美元。这代表其持股比例减少了 2.24%。此次出售在提交给证券交易委员会的文件中披露，您可以通过此链接访问该文件。</p>
</div><ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><ul>
<li>华尔街喜爱的 3 只市值低于 20 美元的中型股</li>
</ul>
</div><p>Michael Raab also recently made the following trade(s):</p>
<div class="lb-trans"><p>Michael Raab 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, February 20th, Michael Raab sold 45,982 shares of Ardelyx stock. The stock was sold at an average price of $5.85, for a total value of $268,994.70.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 2 月 20 日（星期五），Michael Raab 出售了 45,982 股 Ardelyx 股票。股票的平均售价为 5.85 美元，总价值为 268,994.70 美元。</li>
</ul>
</div><h2>Ardelyx Trading Down 4.8%</h2>
<div class="lb-trans"><h2>Ardelyx 股价下跌 4.8%</h2>
</div><p>ARDX stock traded down $0.28 during mid-day trading on Wednesday, reaching $5.55. The company's stock had a trading volume of 2,907,115 shares, compared to its average volume of 4,895,942. Ardelyx, Inc. has a 12 month low of $3.21 and a 12 month high of $8.40. The company has a current ratio of 4.31, a quick ratio of 4.11 and a debt-to-equity ratio of 1.21. The business's 50 day moving average price is $6.88 and its 200 day moving average price is $6.16. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -22.20 and a beta of 0.61.</p>
<div class="lb-trans"><p>在周三的午盘交易中，ARDX 股票下跌 0.28 美元，达到 5.55 美元。该公司的股票交易量为 2,907,115 股，而其平均交易量为 4,895,942 股。Ardelyx, Inc.的 12 个月最低价为 3.21 美元，最高价为 8.40 美元。该公司的流动比率为 4.31，速动比率为 4.11，债务与股本比率为 1.21。该公司的 50 日移动平均价格为 6.88 美元，200 日移动平均价格为 6.16 美元。该公司的市值为 13.6 亿美元，市盈率为-22.20，贝塔值为 0.61。</p>
</div><ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><ul>
<li>Ardelyx 在 2022 年初下滑后是否值得购买</li>
</ul>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03). The business had revenue of $125.22 million for the quarter, compared to the consensus estimate of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.Ardelyx's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.02 earnings per share. On average, equities research analysts predict that Ardelyx, Inc. will post -0.18 EPS for the current year.</p>
<div class="lb-trans"><p>Ardelyx（纳斯达克代码：ARDX - 获取免费报告）最近在 2 月 19 日（星期四）发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为-0.01 美元，低于分析师一致预期的 0.02 美元，差距为 0.03 美元。该公司的季度收入为 1.2522 亿美元，而一致预期为 1.1804 亿美元。Ardelyx 的股本回报率为-40.63%，净利润率为-15.12%。Ardelyx 的季度收入同比增长 7.8%。在去年同期，该公司每股收益为 0.02 美元。根据分析师的预测，Ardelyx, Inc.在当前年度的每股收益将为-0.18 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research analysts recently issued reports on the stock. Raymond James Financial reissued a &#34;strong-buy&#34; rating and set a $19.00 target price on shares of Ardelyx in a research note on Thursday, January 8th. Leerink Partners reaffirmed an &#34;outperform&#34; rating on shares of Ardelyx in a research note on Thursday, March 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Ardelyx in a report on Wednesday, January 21st. Williams Trading set a $17.00 price objective on shares of Ardelyx in a research report on Thursday, March 12th. Finally, Citigroup raised their target price on Ardelyx from $11.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $15.70.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发布了报告。Raymond James Financial 在 1 月 8 日（星期四）的研究报告中重申了对 Ardelyx 的 “强力买入” 评级，并设定了 19.00 美元的目标价。Leerink Partners 在 3 月 12 日（星期四）的研究报告中重申了对 Ardelyx 的 “跑赢大盘” 评级。Weiss Ratings 在 1 月 21 日（星期三）的报告中重申了对 Ardelyx 的 “卖出（d-）” 评级。Williams Trading 在 3 月 12 日（星期四）的研究报告中设定了 17.00 美元的目标价。最后，花旗集团在 1 月 9 日（星期五）的研究报告中将 Ardelyx 的目标价从 11.00 美元上调至 14.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股票给予了强力买入评级，八位分析师给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 15.70 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on ARDX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 ARDX 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in ARDX. DCF Advisers LLC acquired a new stake in shares of Ardelyx in the 2nd quarter worth about $39,000. First Horizon Corp boosted its stake in Ardelyx by 120.4% during the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 4,319 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Ardelyx by 147.0% during the 3rd quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 6,102 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Ardelyx in the third quarter worth approximately $57,000. Finally, Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Ardelyx in the fourth quarter valued at approximately $60,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金最近对 ARDX 的持仓进行了调整。DCF Advisers LLC 在第二季度收购了 Ardelyx 的新股份，价值约 39,000 美元。First Horizon Corp 在第四季度将其在 Ardelyx 的持股增加了 120.4%。First Horizon Corp 目前持有 7,906 股生物制药公司的股票，价值 46,000 美元，此前在上个季度购买了 4,319 股。SBI Securities Co. Ltd.在第三季度将其在 Ardelyx 的持股增加了 147.0%。SBI Securities Co. Ltd.目前持有 10,253 股生物制药公司的股票，价值 56,000 美元，此前在上个季度购买了 6,102 股。瑞士人寿资产管理有限公司在第三季度收购了 Ardelyx 的新股份，价值约 57,000 美元。最后，住友三井信托集团在第四季度收购了 Ardelyx 的新股份，价值约 60,000 美元。目前 58.92% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Ardelyx Company Profile</h2>
<div class="lb-trans"><h2>Ardelyx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（纳斯达克：ARDX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对心肾和胃肠疾病的小分子靶向药物。该公司的主要市场产品 tenapanor（在美国以品牌名 XPHOZAH 销售）已获批准用于治疗接受透析的慢性肾病患者的高磷血症。Ardelyx 的专有方法针对胃肠道中的上皮转运蛋白，提供局部作用并限制全身暴露。</p>
</div><p>Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.</p>
<div class="lb-trans"><p>除了 tenapanor，Ardelyx 的开发管道还包括旨在解决肾病及相关代谢紊乱的其他并发症的治疗方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Ardelyx</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Ardelyx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ardelyx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ardelyx 吗？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Ardelyx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ardelyx 并不在名单上。</p>
</div><p>While Ardelyx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ardelyx 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock

Market Beat

Ardelyx

内幕交易：Ardelyx（纳斯达克代码：ARDX）的首席执行官出售了 41,666 股股票